tiprankstipranks
Advertisement
Advertisement
X4 Pharmaceuticals files $300M mixed securities shelf
PremiumThe FlyX4 Pharmaceuticals files $300M mixed securities shelf
2M ago
X4 Pharmaceuticals announces EC approval of Xolremdi
Premium
The Fly
X4 Pharmaceuticals announces EC approval of Xolremdi
2M ago
X4 Pharmaceuticals reports Q4 EPS (22c), consensus (35c)
Premium
The Fly
X4 Pharmaceuticals reports Q4 EPS (22c), consensus (35c)
3M ago
One new option listing and  option delistings on January 20th
PremiumThe FlyOne new option listing and option delistings on January 20th
5M ago
X4 Pharmaceuticals price target raised to $10 from $7.50 at Stifel
Premium
The Fly
X4 Pharmaceuticals price target raised to $10 from $7.50 at Stifel
7M ago
X4 Pharmaceuticals price target raised to $5 from $3.50 at H.C. Wainwright
Premium
The Fly
X4 Pharmaceuticals price target raised to $5 from $3.50 at H.C. Wainwright
7M ago
X4 Pharmaceuticals announces common stock offering, no amount given
PremiumThe FlyX4 Pharmaceuticals announces common stock offering, no amount given
8M ago
Altimmune appoints Christophe Arbet-Engels as CMO
Premium
The Fly
Altimmune appoints Christophe Arbet-Engels as CMO
9M ago
X4 Pharmaceuticals Announces Major Strategic Restructuring
Premium
Company Announcements
X4 Pharmaceuticals Announces Major Strategic Restructuring
9M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100